Evidence map›Paper›PMID 40856037›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

NamiRNA-Enhancer Network: The Changing Era Challenge and Chance of miRNA.

Lu Chen, Ying Liang, Hongyan Wei, Mengxing Liu, Jin Wu, Wei Li, Wenxuan Li, Yuxiao Jin, Yinshan Li, Wei Zhao and 4 more

Abstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. NamiRNA-Enhancer Network: The Changing Era Challenge and Chance of miRNA.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lu ChenShanghai Public Health Clinical Center and Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute and Laboratory of RNA Epigenetics, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Ying LiangDepartment of Pharmacy and Drug Development Center, Precision Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, China.
Hongyan WeiShanghai Public Health Clinical Center and Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute and Laboratory of RNA Epigenetics, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Mengxing LiuShanghai Public Health Clinical Center and Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute and Laboratory of RNA Epigenetics, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Jin WuResearch and Development Department, Shanghai Epicurer Biotechnology Co., Ltd, Shanghai, 200233, China.
Wei LiShanghai Public Health Clinical Center and Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute and Laboratory of RNA Epigenetics, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Wenxuan LiShanghai Public Health Clinical Center and Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute and Laboratory of RNA Epigenetics, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Yuxiao JinLaboratory Animal Center Fudan University, MOE Frontiers Center for Brain Science, Fudan University, Shanghai, 200032, China.
Yinshan LiNingxia Institution of Clinical Medicine, The Third Clinical Medicine College, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, 750002, China.
Wei ZhaoNingxia Institution of Clinical Medicine, The Third Clinical Medicine College, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, 750002, China.
Min XiaoShanghai Public Health Clinical Center and Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute and Laboratory of RNA Epigenetics, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Kaicheng ZhouShanghai Public Health Clinical Center and Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute and Laboratory of RNA Epigenetics, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Shuai YangShanghai Public Health Clinical Center and Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute and Laboratory of RNA Epigenetics, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Wenqiang YuShanghai Public Health Clinical Center and Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute and Laboratory of RNA Epigenetics, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China.ORCID https://orcid.org/0000-0001-9920-1133

Funding

Key Research and Development Program of Ningxia Hui Autonomous Region of China 2022BEG01003Key Research and Development Program of Ningxia Hui Autonomous Region of China 2023BEG02007Key Research and Development Program of Ningxia Hui Autonomous Region of China 2023BEG03019National Key R&D Program of China 2018YFC1005004National Natural Science Foundation of China 31872814National Natural Science Foundation of China 32270645National Natural Science Foundation of China 82203445Shanghai Sailing Program 23YF1445600
6 · The paper itself

Abstract

MicroRNAs (miRNAs) systematically orchestrate multiple biological processes via gene regulation in various organisms. Conventionally, miRNAs bind to untranslated regions of mRNAs to modulate gene silencing in the cytoplasm. Recent studies have revealed that a subset of miRNAs located in the nucleus can efficiently activate gene transcription by targeting enhancers, named as Nuclear Activating miRNAs (NamiRNAs). The fundamental principle of this regulatory pattern is that NamiRNAs as "wedges" open double strands of genomic DNA and provide the prerequisite for RNA polymerase II-mediated transcription. Specifically, NamiRNAs bind to their target enhancers and form the hybrids of miRNAs and single-stranded DNA, which are recognized by Argonaute 2 (AGO2) to maintain the single-stranded state. Meanwhile, AGO2 protects these miRNA-DNA hybrids from RNase H-mediated degradation to maintain their stability. Additionally, NamiRNAs induce H3K27ac enrichment at target enhancers and put them into an active state conducive to gene activation. Notably, similar to NamiRNAs, Human Identical Sequences as exogenous small RNAs as critical pathogenic factors for RNA viruses, facilitate infectious disease progression. Collectively, this review systematically elucidates the theory of NamiRNA-Enhancer-mediated Gene Activation in combination with corresponding evidence, summarizes the functions and challenges of NamiRNAs, and discusses their potential in fundamental research and clinical applications.

Indexed as

Enhancer Elements, GeneticMicroRNAsAnimalsArgonaute ProteinsGene Expression RegulationHumansArgonaute ProteinsMicroRNAsenhancerhuman identical sequencesNamiRNAssmall nucleotide drugstranscriptional activation

Identifiers

PMID40856037
PMCPMC12533385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.